Physician profile
Herbert Secouler
NPI 1851371652
$618.52
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $149 · 2022: $28.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $74.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $72.60 | 2019-2020 | |
| Pfizer INC. | $71.96 | 2019-2020 | |
| Novo Nordisk INC | $56.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.57 | 2019-2020 | |
| Abbvie INC. | $43.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.21 | 2019 | |
| Lilly USA, LLC | $30.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.41 | 2019-2020 | |
| Astellas Pharma US INC | $18.64 | 2019 | |
| Kaleo, INC. | $18.46 | 2019 | |
| Allergan, INC. | $16.49 | 2019 | |
| Merck Sharp & Dohme LLC | $16.12 | 2019 | |
| Amarin Pharma, INC. | $14.78 | 2019 | |
| Amgen INC. | $14.72 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $14.59 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.29 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Secouler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.